SCHEMBL3933129

SCHEMBL3933129

c1ncn2c1CCC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16373622 0.73 NAMPT (0.31)
SCHEMBL1737418 0.70 IDO1 (0.34)
SCHEMBL6068456 0.68
SCHEMBL9941956 0.67
SCHEMBL9944699 0.67 NAMPT (0.35)
SCHEMBL18366014 0.66 CRBN (0.37)
SCHEMBL18366012 0.65 BRD4 (0.39)
SCHEMBL7767385 0.64
SCHEMBL10361609 0.63 NAMPT (0.33)
SCHEMBL18887998 0.62 KDM4E (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040254158-A1 Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders BRISTOL-MYERS SQUIBB COMPANY 2004-12-16 US claimed
US-12479849-B2 EGFR inhibitors for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2025-11-25 US disclosed
EP-4648765-A1 MUTANT-SELECTIVE EGFR INHIBITORS Dana-Farber Cancer Institute, Inc. (US) 2025-11-19 EP disclosed
US-12344613-B2 EGFR inhibitor for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2025-07-01 US disclosed
CN-120202200-A Oxo-isoindolinyl substituted tetrahydropyrimidinedione-based compounds and applications thereof 标新生物医药科技(上海)有限公司 2025-06-24 CN disclosed
EP-4562003-A1 NOVEL 7-SUBSTITUTED INDOLE SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-06-04 EP disclosed
CN-119585257-A Novel 7-substituted indole sulfonamide derivatives 豪夫迈·罗氏有限公司 2025-03-07 CN disclosed
US-20240382483-A1 HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER BLUEPRINT MEDICINES CORPORATION 2024-11-21 US disclosed
US-20240308981-A1 HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER BLUEPRINT MEDICINES CORPORATION 2024-09-19 US disclosed
US-20240300946-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2024-09-12 US disclosed
EP-0873292-B1 IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES UNION CARBIDE CHEM PLASTIC (US) 2001-12-19 EP disclosed
EP-0873292-A1 IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 1998-10-28 EP disclosed
US-5731472-A HETEROCYCLIC NITROGEN COMPOUNDS UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 1998-03-24 US disclosed
WO-1997020798-A1 IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 1997-06-12 WO disclosed
EP-0728752-A1 Triazole compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-08-28 EP disclosed
US-5405861-A Fungicides TAKEDA CHEMICAL INDUSTRIES, CO., LTD. (JP) 1995-04-11 US disclosed
EP-0421210-A2 Triazole compounds, their production and use Takeda Chemical Industries, Ltd. (JP) 1991-04-10 EP disclosed
US-4895956-A ANTIINFLAMMATORY, ANALGESIC HISAMITSU PHARMACEUTICAL CO., LTD. (JP) 1990-01-23 US disclosed
EP-0307034-A1 Novel 3-aroyl-6,7-dihydro-5h-pyrrolo[1,2-c] imidazole-7-carboxylic acid derivatives HISAMITSU PHARMACEUTICAL CO., INC. (JP) 1989-03-15 EP disclosed
US-4460709-A Process for producing oxygen-containing organic compounds AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) 1984-07-17 US disclosed